相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis
Giovanni Palladini et al.
BLOOD (2014)
Auto-SCT improves survival in systemic light chain amyloidosis: a retrospective analysis with 14-year follow-up
S. Parmar et al.
BONE MARROW TRANSPLANTATION (2014)
A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis
Ashutosh D. Wechalekar et al.
BLOOD (2013)
The diagnosis and characteristics of renal heavy-chain and heavy/light-chain amyloidosis and their comparison with renal light-chain amyloidosis
Samih H. Nasr et al.
KIDNEY INTERNATIONAL (2013)
Revised Prognostic Staging System for Light Chain Amyloidosis Incorporating Cardiac Biomarkers and Serum Free Light Chain Measurements
Shaji Kumar et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Multiple myeloma: 2011 update on diagnosis, risk-stratification, and management
S. Vincent Rajkumar
AMERICAN JOURNAL OF HEMATOLOGY (2011)
Changes in serum-free light chain rather than intact monoclonal immunoglobulin levels predicts outcome following therapy in primary amyloidosis
Shaji K. Kumar et al.
AMERICAN JOURNAL OF HEMATOLOGY (2011)
Bortezomib and high-dose melphalan conditioning for stem cell transplantation for AL amyloidosis: a pilot study
Vaishali Sanchorawala et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
Amyloidosis: Pathogenesis and New Therapeutic Options
Giampaolo Merlini et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Long-term outcomes of patients with light chain amyloidosis (AL) after renal transplantation with or without stem cell transplantation
Sandra M. S. Herrmann et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2011)
Serum immunoglobulin free light-chain measurement in primary amyloidosis: prognostic value and correlations with clinical features
Shaji Kumar et al.
BLOOD (2010)
High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis
Arnaud Jaccard et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial
Vaishali Sanchorawala et al.
BLOOD (2007)
Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis
Ashutosh D. Wechalekar et al.
BLOOD (2007)
Transplantation for amyloidosis
Morie A. Gertz et al.
CURRENT OPINION IN ONCOLOGY (2007)
Autologous stem-cell transplantation in progressing amyloidosis is associated with severe transplant-related toxicity
N Worel et al.
WIENER KLINISCHE WOCHENSCHRIFT (2006)
Serum free light-chain responses after high-dose intravenous melphalan and autologous stem cell transplantation for AL (primary) amyloidosis
V Sanchorawala et al.
BONE MARROW TRANSPLANTATION (2005)
Indications for high-dose chemotherapy with autologous stem cell support in patients with systemic amyloid light chain amyloidosis
SO Schonland et al.
TRANSPLANTATION (2005)
Renal response after high-dose melphalan and stem cell transplantation is a favorable marker in patients with primary systemic amyloidosis
N Leung et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2005)
Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis
MA Gertz et al.
AMERICAN JOURNAL OF HEMATOLOGY (2005)
High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: An 8-year study
M Skinner et al.
ANNALS OF INTERNAL MEDICINE (2004)
Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: A staging system for primary systemic amyloidosis
A Dispenzieri et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Stem cell transplantation for the management of primary systemic amyloidosis
MA Gertz et al.
AMERICAN JOURNAL OF MEDICINE (2002)
An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis
V Sanchorawala et al.
BONE MARROW TRANSPLANTATION (2001)
分享论文
